Influenza A virus vaccines and inhibitors

US8455621B2 · kind B2 · utility

Assignees

• Rutgers, the State University of New Jersey · US
• The Board of Regents of the University of Texas System · US

Inventors

• Robert M. Krug · Austin, US
• Karen Y. Twu · San Mateo, US
• Rei-Lin Kuo · Taipei, TW
• Gaetano T. Montelione · Highland Park, US
• Edward Arnold · Montgomery, US
• Kalyan Das · Edison, US
• LiChung Ma · Plainsboro, US
• Rong Xiao · Princeton, US

Key dates

• Filing date: Feb 17, 2010
• Grant date: Jun 4, 2013
• Expiry date: Jan 30, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/16162
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.